Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1

Virology Journal

Volumn 5, Issue , 2008, Pages

  Lim, Angeline P C ^a   Wong, Steven K K ^a   Chan, Annie H Y ^a   Chan, Conrad E Z ^a   Ooi, Eng Eong ^a   Hanson, Brendon J ^a  

^a DSO NATIONAL LABORATORIES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VN04 2; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; INFLUENZA VIRUS A H5N1; NONHUMAN; PATHOGENICITY; VIRUS LIKE AGENT; VIRUS STRAIN; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; CLASSIFICATION; GENETICS; HUMAN; IMMUNOLOGY; INDONESIA; METABOLISM; MOUSE; MUTATION; SERODIAGNOSIS; VIRION;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INDONESIA; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE; MUTATION; NEUTRALIZATION TESTS; VIRION;

EID: 47749151914     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-80     Document Type: Article

References (19)

1. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. EC Claas AD Osterhaus R van Beek JC De Jong GF Rimmelzwaan DA Senne S Krauss KF Shortridge RG Webster, Lancet 1998 351 472 477 10.1016/S0140-6736(97)11212-0 9482438
2. A pandemic warning? JC de Jong EC Claas AD Osterhaus RG Webster WL Lim, Nature 1997 389 554 10.1038/39218 9335492
3. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. KY Yuen PK Chan M Peiris DN Tsang TL Que KF Shortridge PT Cheung WK To ET Ho R Sung AF Cheng, Lancet 1998 351 467 471 10.1016/S0140-6736(98)01182-9 9482437
4. Global task force for influenza. R Fouchier T Kuiken G Rimmelzwaan A Osterhaus, Nature 2005 435 419 420 10.1038/435419a 15917779
5. H5N1 influenza-continuing evolution and spread. RG Webster EA Govorkova, N Engl J Med 2006 355 2174 2177 10.1056/NEJMp068205 17124014
6. World: Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO on 11 January 2008. Healh Organization Epidemic and Pandemic Alert and Response 2008 http://www.who.int/csr/disease/avian_influenza/ country/cases_table_ 2008_01_11/en/index.html
7. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. CP Simmons NL Bernasconi AL Suguitan K Mills JM Ward NV Chau TT Hien F Sallusto Q Ha do J Farrar, PLoS Med 2007 4 e178 17535101 10.1371/journal.pmed.0040178
8. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. BJ Hanson AC Boon AP Lim A Webb EE Ooi RJ Webby, Respir Res 2006 7 126 17040574 10.1186/1465-9921-7-126
9. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. J Lu Z Guo X Pan G Wang D Zhang Y Li B Tan L Ouyang X Yu, Respiratory Research 2006 7 43 16553963 10.1186/1465-9921-7-43
10. Treatment with convalescent plasma for influenza A (H5N1) infection. B Zhou N Zhong Y Guan, N Engl J Med 2007 357 1450 1451 10.1056/NEJMc070359 17914053
11. Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. H Chen GJ Smith KS Li J Wang XH Fan JM Rayner D Vijaykrishna JX Zhang LJ Zhang CT Guo, Proc Natl Acad Sci USA 2006 103 2845 2850 16473931 10.1073/pnas.0511120103
12. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. E Hoffmann AS Lipatov RJ Webby EA Govorkova RG Webster, Proc Natl Acad Sci USA 2005 102 12915 12920 16118277 10.1073/pnas.0506416102
13. The Influenza Virus Resource at the National Center for Biotechnology Information. Y Bao P Bolotov D Dernovoy B Kiryutin L Zaslavsky T Tatusova J Ostell D Lipman, J Virol 2008 82 596 601 17942553 10.1128/JVI.02005-07
14. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. J Stevens O Blixt TM Tumpey JK Taubenberger JC Paulson IA Wilson, Science 2006 312 404 410 10.1126/science.1124513 16543414
15. An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin. LE Brown JM Murray DO White DC Jackson, Arch Virol 1990 114 1 26 10.1007/BF01311008 1699509
16. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. J Szecsi B Boson P Johnsson P Dupeyrot-Lacas M Matrosovich HD Klenk D Klatzmann V Volchkov FL Cosset, Virol J 2006 3 70 16948862 10.1186/1743-422X-3-70
17. Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against Venezuelan equine encephalitis virus. AA Kolokoltsov E Wang TM Colpitts SC Weaver RA Davey, Am J Trop Med Hyg 2006 75 702 709 17038698
18. Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins. AA Kolokoltsov SC Weaver RA Davey, J Virol 2005 79 756 763 15613303 10.1128/JVI.79.2.756-763.2005
19. World: Towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. Healh Organization Epidemic and Pandemic Alert and Response 2007 http://www.who.int/csr/disease/avian_influenza/guidelines/ nomenclature/en/index.html